P/E ratio for CONMED (CNMD)
P/E ratio as of April 2024 (TTM): 32.6
According to CONMED's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 32.5789. At the end of 2022 the company had a P/E ratio of -32.1.
P/E ratio history for CONMED from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -32.1 | -148.48% |
| 2021 | 66.2 | -80.48% |
| 2020 | 339 | 209.56% |
| 2019 | 110 | 149.33% |
| 2018 | 44.0 | 71.68% |
| 2017 | 25.6 | -69.85% |
| 2016 | 84.9 | 112.11% |
| 2015 | 40.0 | 5.1% |
| 2014 | 38.1 | 16.55% |
| 2013 | 32.7 | 67.26% |
| 2012 | 19.5 | -96.95% |
| 2011 | 642 | 2473.8% |
| 2010 | 24.9 | -55.16% |
| 2009 | 55.6 | 220.56% |
| 2008 | 17.3 | 8.85% |
| 2007 | 15.9 | -131.71% |
| 2006 | -50.3 | -333.67% |
| 2005 | 21.5 | -14.48% |
| 2004 | 25.2 | 46.89% |
| 2003 | 17.1 | 10.13% |
| 2002 | 15.5 | -20.81% |
| 2001 | 19.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -68.01% | 🇺🇸 USA |
 Medtronic MDT | 29.1 | -10.57% | 🇮🇪 Ireland |
 Boston Scientific BSX | 89.3 | 174.23% | 🇺🇸 USA |
 Stryker Corporation SYK | 49.5 | 51.96% | 🇺🇸 USA |
 Teleflex TFX | 24.0 | -26.22% | 🇺🇸 USA |
 Integra LifeSciences IART | 23.3 | -28.52% | 🇺🇸 USA |
 Smith & Nephew
SNN | 21.3 | -34.67% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.